玛舒拉沙韦片 | China Drugs ListSuraxavir Marboxil Tablets | China Drugs List
本页为公开参考信息，不构成医疗建议、处方或药品供应要约。请向持证专业人士确认当前批准情况、可获得性及适用性。
- 企业
- 江西科睿药业有限公司Jiangxi Kerui Pharmaceutical Co., Ltd.
- 药品类型
- 化学药Chemical medicine
- 治疗领域
- 感染性疾病Infectious diseases
- 公开来源记录的适应症
- 治疗既往健康的12岁及以上青少年和成人的单纯性甲型或乙型流感；不包括存在流感相关并发症高风险的患者。说明书要求在症状出现后48小时内开始用药。Treatment of uncomplicated influenza A or B in previously healthy adults and adolescents aged 12 years and older, excluding patients at high risk of influenza-related complications. The prescribing information requires treatment to begin within 48 hours of symptom onset.
- 适应症来源与口径
- 2026-06-26
- 说明书信息局限
- 已取得完整官方药品说明书。 中国大陆说明书。Complete official prescribing information obtained. Mainland China label.
- 中国可获得性状态
- 已核实中国历史批准记录；尚未逐项核查每个产品目前是否持续上市销售。Historical Chinese approval verified; current continuous market availability has not been checked for every product.
- 海外状态
- 待逐一核查各市场。Market-by-market verification pending.
- 医保分类
- 已纳入国家医保（乙类）Included in national insurance (Category B)
- 医保版本
- 2025版；2026年1月1日起执行2025 edition; effective 1 January 2026
- 医保限制
- 限既往健康的12岁及以上青少年和成人单纯性甲型和乙型流感患者的治疗，不包括存在流感相关并发症高风险的患者。Limited to treatment of uncomplicated influenza A or B in previously healthy adults and adolescents aged 12 years and older, excluding patients at high risk of influenza-related complications.
- 医保期限
- 2026-01-01 至 2027-12-312026-01-01 to 2027-12-31
- 医保核查说明
- 按成分／剂型名称精确或标准化匹配。报销仍取决于剂型及目录所列支付限制。Matched by exact or normalized ingredient/formulation name. Reimbursement still depends on the dosage form and listed payment restrictions.